Who are Adjunct brexpiprazole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abilify MyCite®, Aripiprazole (Fixed dose), Brexpiprazole +ADT, Brexpiprazole (OPC-34712), OPC-34712FUM/ Brexpiprazole fumarate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adjunct-brexpiprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Adjunct brexpiprazole — Competitive Intelligence Brief

Adjunct brexpiprazole (Adjunct brexpiprazole) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-dopamine activity modulator (SDAM). Area: Psychiatry.

phase 3 Serotonin-dopamine activity modulator (SDAM) Dopamine D2 receptor, Serotonin 5-HT1A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Adjunct brexpiprazole (Adjunct brexpiprazole) — H. Lundbeck A/S. Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, used as an adjunctive treatment to enhance antidepressant efficacy.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Adjunct brexpiprazole TARGET	Adjunct brexpiprazole	H. Lundbeck A/S	phase 3	Serotonin-dopamine activity modulator (SDAM)	Dopamine D2 receptor, Serotonin 5-HT1A receptor
Abilify MyCite®	Abilify MyCite®	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic with digital adherence monitoring	Dopamine D2 receptor, serotonin 5-HT1A receptor
Aripiprazole (Fixed dose)	Aripiprazole (Fixed dose)	Otsuka Pharmaceutical Co., Ltd.	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT1A receptor
Brexpiprazole +ADT	Brexpiprazole +ADT	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Atypical antipsychotic (dopamine D2 partial agonist)	Dopamine D2 receptor, Serotonin 5-HT1A receptor
Brexpiprazole (OPC-34712)	Brexpiprazole (OPC-34712)	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Atypical antipsychotic; serotonin-dopamine activity modulator (SDAM)	Dopamine D2 receptor (partial agonist); serotonin 5-HT1A receptor (partial agonist); serotonin 5-HT2A receptor (antagonist)
OPC-34712FUM/ Brexpiprazole fumarate	OPC-34712FUM/ Brexpiprazole fumarate	Otsuka Pharmaceutical Co., Ltd.	phase 3	Serotonin-dopamine activity modulator (SDAM); atypical antipsychotic	Dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor (partial agonist), serotonin 5-HT2A receptor (antagonist)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-dopamine activity modulator (SDAM) class)

H. Lundbeck A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adjunct brexpiprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/adjunct-brexpiprazole. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab